Uromesan Special Precautions

The occurrence of hypersensitivity reactions (hyperergic reactions) following Mesna therapy has been reported more frequently in patients with autoimmune disorders than in tumour patients. Skin and mucosal reactions have been observed (rash, urticaria, exanthema, enanthema), a rise in liver transaminases and non-specific common symptoms like fever, exhaustion, nausea and vomiting. Isolated circulatory reactions with hypotension and tachycardia have been observed as well. Protection of the urinary tract with Mesna should therefore only be undertaken in patients following careful risk-benefit analysis and under medical supervision.
As Mesna is used as a uroprotector in the context of cytostatic treatment with Oxazaphosphorines, its use during pregnancy and lactation is governed by the criteria for this type of cytostatic therapy. Animal studies have shown no evidence of embryotoxic or teratogenic effects of Mesna.
The protective action of Mesna applies only to the urinary tract. All other recommended precautions are unaffected by its use and recommendations relating to them remain in force.